The use of menopausal hormone therapy in women survivors of gynecological cancer: safety report based on systematic reviews and meta-analysis

The data collected during the last two decades on the effects of Hormonal menopause treatment (HMT) could help to provide a safer and more effective long term-treatment of menopause symptoms and possible complications such as osteoporotic fractures, cognitive impairment, or cardiovascular conditions, as well as an improved quality of life. Having a history of suffering from gynecological cancer (endometrial, cervical or ovarian) is one of the conditions that most strongly determines the use of any form of HMT due to the concerns associated with a possible recurrence of the disease. Objective: To create a set of eligibility criteria for the use of HMT in gynecological cancer patients. Methods: The study was registered in PROSPERO (registration number CRD42020166658). Results: Ovarian cancer survivors who use HMT have better overall survival, disease-free survival, and lower recurrence rates than women survivors who do not use HMT. Endometrial cancer survivors who use HMT do not have a higher rate of disease recurrence than those survivors who do not use HMT. Cervical cancer survivors who use HMT do not have a higher rate of disease recurrence than those survivors who do not use HMT. Conclusion: HMT is safe in women who have suffered from most of non-advanced gynecological cancers.

Menopausal hormone therapy; Gynecological cancer survivors

[1] de Villiers TJ, Hall JE, Pinkerton JV, Pérez SC, Rees M, Yang C, et al. Revised global consensus statement on menopausal hormone therapy. Maturitas. 2016; 91: 153–155.

[2] Davey DA. Menopausal hormone therapy: a better and safer future. Climacteric. 2018; 21: 454–461.

[3] Chester RC, Kling JM, Manson JE. What the Women’s Health Ini-tiative has taught us about menopausal hormone therapy. Clinical Cardiology. 2018; 41: 247–252.

[4] Stepan JJ, Hruskova H, Kverka M. Update on Menopausal Hor-mone Therapy for Fracture prevention. Current Osteoporosis Reports. 2019; 17: 465–473.

[5] Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016; 19: 109–150.

[6] The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2018; 25: 1362–1387.

[7] Gaffield ML, Kiarie J. Who medical eligibility criteria update. Contraception. 2016; 94: 193-194.

[8] Mendoza N, Juliá MD, Galliano D, Coronado P, Díaz B, Fontes J, et al. Spanish consensus on premature menopause. Maturitas. 2015; 80: 220–225.

[9] Liberati A, Altman D G, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of Clinical Epidemiology. 2009; 62: e1–e34.

[10] Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane Handbook for Systematic Reviews of Interventions. 2nd edn. Chichester: John Wiley & Sons. 2019.

[11] Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. British Medical Journal. 2016; 355: i4919.

[12] Manager (RevMan) (Version 5.4.) [Computer program]. The Cochrane Collaboration. 2020. Available at: https://training.cochrane.org/online-learning/core-software-c ochrane-reviews/revman (Accessed: 10 February 2021).

[13] Schünemann H, Brożek J, Guyyat G, Oxman A. Handbook for grading the quality of evidence and the strength of recommen-dations using the GRADE approach. 2013. Available at: https: //gdt.gradepro.org/app/handbook/handbook.html (Accessed: 10 February 2021).

[14] Eeles RA, Morden JP, Gore M, Mansi J, Glees J, Wenczl M, et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial. Journal of Clinical Oncology. 2015; 33: 4138–4144.

[15] Li L, Pan Z, Gao K, Zhang W, Luo Y, Yao Z, et al. Impact of post-operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters. 2012; 3: 244–249.

[16] Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer. 1999; 86: 1013–1018.

[17] Eeles RA, Tan S, Wiltshaw E, Fryatt I, A’Hern RP, Shepherd JH, et al. Hormone replacement therapy and survival after surgery for ovarian cancer. British Medical Journal. 1991; 302: 259–262.

[18] Ursic-Vrscaj M, Bebar S, Zakelj MP. Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. Menopause. 2001; 8: 70–75.

[19] Mascarenhas C, Lambe M, Bellocco R, Bergfeldt K, Riman T, Pers-son I, et al. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. International Journal of Cancer. 2006; 119: 2907–2915.

[20] Wen Y, Huang H, Huang H, Wu M, Shen K, Pan L. The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China. Climacteric. 2013; 16: 673–681.

[21] Power L, Lefas G, Lambert P, Kim D, Evaniuk D, Lotocki R, et al. Hormone use after nonserous epithelial ovarian cancer: overall and disease-free survival. Obstetrics and Gynecology. 2016; 127: 837–847.

[22] Zhang Y, Chen J, Lu W, Li B, Zhu Q, Wan X. Efficacy of post-operative hormone replacement therapy on prognosis of patients with serous ovarian carcinoma. Chinese Medical Journal. 2016; 129: 1316–1321.

[23] Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS. Ran-domized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology. 2006; 24: 587–592.

[24] Ayhan A, Taskiran C, Simsek S, Sever A. Does immediate hormone replacement therapy affect the oncologic outcome in en-dometrial cancer survivors? International Journal of Gynecological Cancer. 2006; 16: 805–808.

[25] Suriano KA, McHale M, McLaren CE, Li KT, Re A, DiSaia PJ. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstetrics and Gynecology. 2001; 97: 555–560.

[26] Arteaga-Gómez AC, Castellanos-Barroso G, Colin-Valenzuela A, García-Vargas J, Márquez-Acosta G, Reyes-Muñoz E. Hormone therapy effect in postmenopausal women with history of endometrial cancer. Ginecologia Y Obstetricia de Mexico. 2011; 79: 11–17.

[27] Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstetrics and Gynecology. 1986; 67: 326-330.

[28] Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecologic Oncology. 1990; 36: 189–191.

[29] Chapman JA, DiSaia PJ, Osann K, Roth PD, Gillotte DL, Berman ML. Estrogen replacement in surgical stage I and II endometrial cancer survivors. American Journal of Obstetrics and Gynecology. 1996; 175: 1195–1200.

[30] Lim S, Kim YH, Lee KB, Lee JM. The influence of hormone therapy with drospirenone-estradiol on endometrioid type endometrial cancer patients. Journal of Gynecologic Oncology. 2018; 29: e72.

[31] Cho HW, Ouh YT, Lee JK, Hong JH. Effects of hormone ther-apy on recurrence in endometrial cancer survivors: a nationwide study using the Korean Health Insurance Review and Assessment Service database. Journal of Gynecologic Oncology. 2019; 30: e51.

[32] Ploch E. Hormone replacement therapy in patients after cervical cancer treatment. Gynecologic Oncology. 1987; 26: 169–177.

[33] Rees M, Angioli R, Coleman RL, Glasspool R, Plotti F, Simoncini T, et al. European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. Maturitas. 2020; 134: 56–61.

[34] Saeaib N, Peeyananjarassri K, Liabsuetrakul T, Buhachat R, Myriokefalitaki E. Hormone replacement therapy after surgery for epithelial ovarian cancer. Cochrane Database of Systematic Re-views. 2020; 1: CD012559.

[35] Pergialiotis V, Pitsouni E, Prodromidou A, Frountzas M, Perrea DN, Vlachos GD. Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis. Menopause. 2016; 23: 335–342.

[36] Edey KA, Rundle S, Hickey M. Hormone replacement therapy for women previously treated for endometrial cancer. The Cochrane Database of Systematic Reviews. 2018; 5: CD008830.

[37] Shim S, Lee SJ, Kim S. Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis. European Journal of Cancer. 2014; 50: 1628–1637.

[38] O’Donnell RL, Clement KM, Edmondson RJ. Hormone replacement therapy after treatment for a gynaecological malignancy. Current Opinion in Obstetrics & Gynecology. 2016; 28: 32–41.

[39] Di Donato V, Palaia I, D’Aniello D, Musacchio L, Santangelo G, Di mauro F, et al. Does hormone replacement therapy impact the prognosis in endometrial cancer survivors? A systematic review. Oncology. 2020; 98: 195–201.

[40] Angioli R, Luvero D, Armento G, Capriglione S, Plotti F, Scaletta G, et al. Hormone replacement therapy in cancer survivors: utopia? Critical Reviews in Oncology/Hematology. 2018; 124: 51–60.

[41] Deli T, Orosz M, Jakab A. Hormone replacement therapy in cancer survivors – review of the literature. Pathology & Oncology Research. 2019; 26: 63–78.

[42] Liu Y, Ma L, Yang X, Bie J, Li D, Sun C, et al. Menopausal hor-mone replacement therapy and the risk of ovarian cancer: a meta-analysis. Frontiers in Endocrinology. 2019; 10: 801.

[43] Collaborative Group On Epidemiological Studies Of Ovarian Cancer, Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, et al. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet. 2015; 385: 1835–1842.

[44] Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. Journal of the American Medical Association. 2013; 310: 1353–1568.

[45] Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005; 365: 1543–1551.

[46] Sjögren LL, Mørch LS, Løkkegaard E. Hormone replacement therapy and the risk of endometrial cancer: a systematic review. Maturitas. 2016; 91: 25–35.

[47] Tempfer CB, Hilal Z, Juhasz-Boess, Rezniczek GA. Cancers (Basel) menopausal hormone therapy and risk of endometrial cancer: a systematic review. Cancers. 2020; 12: 2195.

[48] Roura E, Travier N, Waterboer T, de Sanjosé S, Bosch FX, Pawlita M, et al. The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: results from the EPIC cohort. PLoS ONE. 2016; 11: e0147029.